Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
ICGC article lays foundation for the coming era of cancer genomic research

ICGC article lays foundation for the coming era of cancer genomic research

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Analysis of high-throughput sequencing data reveals new genes linked to chronic lymphocytic leukemia

Analysis of high-throughput sequencing data reveals new genes linked to chronic lymphocytic leukemia

Researchers develop promising metal-based compound to fight kidney cancer

Researchers develop promising metal-based compound to fight kidney cancer

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

New treatment option available for CLL patients in Manitoba and Saskatchewan

New treatment option available for CLL patients in Manitoba and Saskatchewan

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD